Is COGT a good stock to buy? We came across a bullish thesis on Cogent Biosciences, Inc. on X.com by seedy19tron. In this article, we will summarize the bulls’ thesis on COGT. Cogent Biosciences, Inc.'s share was trading at $34.81 as of June 1st.
Likoper/Shutterstock.com
Cogent Biosciences (COGT) is a clinical-stage oncology company focused on KIT mutation-driven diseases, primarily systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). Its lead ****** et bezuclastinib is a highly selective type I KIT inhibitor targeting KIT D816V, positioning it as a differentiated therapy in mast-cell driven oncology. Beyond its lead program, the company is advancing a broader pipeline including a pan-KRAS(ON) inhibitor CGT1815, a JAK2 inhibitor CGT1145, and FGFR2/3 ****** ets, expanding its optionality across solid tumors and hematologic malignancies.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential